The commentary, published in the Journal of Cancer Research and Clinical Oncology, examines a 2026 review by Xue and Chen that surveyed more than 150 studies on artificial intelligence, lung ground-glass nodules, adenocarcinoma and carcinogenic driver genes. Ground-glass nodules are hazy regions on CT scans that do not completely obscure the structures beneath them. They can represent early lung adenocarcinoma, a noncancerous lesion or an intermediate condition, making them clinically important but notoriously difficult to classify. The hope behind radiogenomics—the combination of medical imaging and molecular genetics—is that an algorithm might infer a tumor’s biological behavior, including its mutations, from its visual appearance.

This approach relies on the idea that genetic changes can alter the architecture and behavior of cancer cells in ways that eventually become visible in an image. Mutations in genes such as EGFR, for example, can influence cell growth, tissue organization, tumor density and the interaction between a lesion and its surrounding lung. CT scanners record differences in X-ray attenuation across tissue, producing measurements related to density, shape, margins, internal texture and spatial structure. Radiomics converts these images into large numerical datasets, while machine-learning models search for statistical associations between those features and molecular labels obtained from pathology or sequencing.

Deep-learning systems can extend this process by learning image representations directly from pixels or three-dimensional volumes. A model may be trained to distinguish nodules associated with one mutation from those associated with another, or to predict whether a tumor carries a potentially actionable alteration. Performance is often summarized using the area under the receiver operating characteristic curve, or AUC. An AUC of 0.5 indicates performance no better than random guessing, while an AUC of 1.0 represents perfect separation between categories. The studies discussed in the review reported values ranging from roughly 0.64 to above 0.95, depending on the gene, imaging method and patient cohort.

That wide range is precisely where the problem begins, according to V. P. Abel Jopaul and M. Lingaraj, the authors of the new commentary. The review did not explain how its literature was located and selected. It provided no stated databases, search dates, search terms or inclusion and exclusion criteria. Nor did it clarify whether the review was intended to be systematic or narrative. This omission matters because a synthesis containing more than 150 references can appear comprehensive even when the underlying search process is unknown. Without a transparent method, readers cannot determine whether studies with weak, negative or null results were actively sought or whether the review disproportionately captured striking positive findings.

The concern is especially important in a rapidly developing field where studies differ dramatically in design. Some investigations use a small, single-center retrospective cohort, while others combine scans from multiple hospitals. A model trained and tested on images from the same institution may learn local scanning protocols, reconstruction settings or patient-selection patterns rather than biological signals associated with a mutation. This phenomenon, known as dataset shift or shortcut learning, can produce impressive internal accuracy that falls sharply when the model encounters patients from another hospital, scanner manufacturer or demographic group.

Sample size and validation strategy also affect how much confidence can be placed in a reported AUC. In a small dataset, a handful of correctly or incorrectly classified cases can substantially change the estimate. If researchers repeatedly adjust a model after examining test results, the nominal test set may no longer provide an unbiased measure of performance. External validation, ideally using data collected independently at different institutions and at a later time, is therefore essential. Prospective studies are even more informative because they test whether a model can operate under the conditions of real clinical care rather than only within a carefully assembled retrospective database.

The commentary argues that the review presented individual headline numbers without a structured quality assessment. A result with an AUC above 0.95 may sound dramatically more convincing than one near 0.64, but the number alone does not reveal whether the studies used comparable endpoints, reference standards or validation procedures. Genetic status might be established through different sequencing methods, while the definition of a nodule or mutation-positive case may vary between cohorts. A high score from a small, homogeneous sample cannot automatically be treated as stronger evidence than a moderate score from a large, diverse and externally validated study.

The authors also identify a mismatch between the review’s language and the aggregate evidence it cites. In its framing sections, the review describes AI as transformative or revolutionary in connecting imaging phenotypes with oncogenic driver genes. Yet the review also references a systematic analysis reporting a mean AUC of approximately 0.64 for predicting driver mutations from histopathological images, with EGFR prediction reaching about 0.79. Those figures suggest that the field has detected meaningful signals but has not yet demonstrated consistently reliable performance suitable for routine clinical decision-making. An average AUC near 0.64 indicates modest discrimination, and even a value around 0.79, while potentially useful, does not by itself establish clinical utility.

This distinction between detecting a statistical association and delivering a clinically useful test is central. A model may identify mutation-related image patterns without being accurate enough to replace tissue sampling or guide treatment independently. Lung cancer therapy can depend on the presence of specific genomic alterations, and a false negative could deny a patient a targeted treatment, while a false positive could lead clinicians toward an inappropriate therapy. Before imaging-based predictions can influence such decisions, researchers must establish calibration, reproducibility, clinical benefit and safety, as well as performance across different populations and healthcare systems.

The critique does not dismiss AI radiogenomics or the review’s value. Xue and Chen’s article maps a broad research landscape that includes CT feature extraction, multimodal data fusion, prognostic modeling, federated learning and regulatory considerations. Such a map can help newcomers understand how imaging, pathology, sequencing and machine learning are being combined. But Jopaul and Lingaraj argue that its usefulness would increase if the evidence were presented with a declared search strategy, a structured comparison of studies and an appraisal of bias and validation quality. They also call for conclusions whose confidence matches the field’s average results rather than its most spectacular individual experiments. The message is likely to resonate beyond lung cancer: AI can find patterns at extraordinary scale, but trustworthy medical science depends on showing how those patterns were discovered, how often they hold up and whether they improve care for real patients.

Lung cancer remains one of the deadliest malignancies worldwide, burdened by late diagnosis and high recurrence rates. Traditional diagnostics, while effective to a degree, often rely on invasive biopsy techniques that carry significant risks and provide limited temporal insight into tumor evolution. Radiogenomics emerges as a game-changer by leveraging imaging biomarkers derived from CT, MRI, and PET scans, then correlating them with comprehensive genomic profiles obtained from tissue samples or liquid biopsies. This convergence enables a multi-dimensional characterization of tumors, capturing spatial and molecular heterogeneity with unprecedented detail.

The core of radiogenomic research lies in decoding how specific genetic mutations and expression patterns manifest in imaging phenotypes. For lung cancer, this means that differences in tumor texture, shape, and metabolic activity visible on scans can be causally linked to genomic alterations such as EGFR mutations, ALK rearrangements, or TP53 status. By developing predictive models, researchers can non-invasively infer a tumor’s molecular landscape, effectively turning routine imaging into a powerful genomic proxy. Such models promise to guide clinical decision-making, especially for patients for whom biopsies are infeasible or risky.

Apart from diagnostics, radiogenomics also provides critical insight into therapeutic resistance mechanisms. Tumors frequently evolve under treatment pressure, acquiring new mutations that enable survival against targeted therapies or immunotherapy. Traditional genomic profiling from static biopsies may miss these dynamic transitions. However, serial imaging combined with real-time genomic data allows clinicians to monitor these changes longitudinally. This approach brings adaptive treatment strategies closer to reality, where therapy can be adjusted proactively based on the tumor’s evolving genomic and radiographic profile.

The implications for personalized medicine in lung cancer are profound. Radiogenomics fosters a precision oncology model where treatment is not only tailored to a static genetic snapshot but continually refined by integrating radiological and molecular shifts. This integration could optimize drug selection, timing of interventions, and monitoring of minimal residual disease without subjecting patients to repeated invasive procedures. Moreover, it could help in stratifying patients more accurately in clinical trials, enriching them for those most likely to benefit from novel agents, thereby accelerating therapeutic advancements.

Technological advancements underpinning radiogenomics are equally noteworthy. Artificial intelligence (AI) and machine learning algorithms play a pivotal role in analyzing vast datasets of imaging and genomic information. These computational tools sift through complex patterns, identifying subtle correlations invisible to the human eye. By training on diverse patient cohorts, AI-driven radiogenomic models improve their predictive accuracy and robustness, setting the stage for their incorporation into routine clinical workflows.

Furthermore, the integration of liquid biopsies into radiogenomic workflows amplifies its utility. Circulating tumor DNA (ctDNA) and other biomarkers present in blood provide minimally invasive means of capturing the tumor’s genomic alterations in real time. Combining liquid biopsy data with imaging signatures enhances the sensitivity and specificity of tumor characterization. This synergy holds promise for early detection of lung cancer relapse and for monitoring response to systemic therapies, enabling a more agile and patient-centric treatment paradigm.

Despite its evident promise, radiogenomics faces several challenges before it can be universally adopted. Standardization of imaging protocols, genomic sequencing methods, and data integration frameworks is paramount. Differences in scanner settings, genetic assay platforms, and bioinformatics pipelines can introduce variability that complicates model generalization. Collaborative efforts across institutions and regulatory guidance will be essential to ensure reliability and reproducibility.

Ethical considerations must also be addressed, especially regarding data privacy and patient consent. The comprehensive datasets required for radiogenomic analyses include sensitive medical and genetic information. Robust frameworks to safeguard data security and transparent communication with patients about the use of their data are critical for building trust and promoting wider acceptance of these technologies.

Economic factors will influence the pace at which radiogenomics is incorporated into healthcare systems. The initial investment in high-throughput sequencing, advanced imaging, and computational infrastructure is substantial. However, cost-effectiveness analyses suggest that the ability to refine treatment choices, avoid ineffective therapies, and reduce invasive procedures could translate into long-term savings and improved patient outcomes.

Beyond lung cancer, the principles of radiogenomics are gaining traction across various malignancies, signaling a paradigm shift in oncology that emphasizes integrative approaches to tumor biology. As research evolves, future directions may include the integration of radiomics, genomics, proteomics, and metabolomics into a unified diagnostic platform. Such a holistic perspective aims to capture the full complexity of cancer and personalize interventions at every stage.

Clinicians and researchers alike are optimistic that radiogenomics will soon bridge the gap between imaging and molecular pathology, transforming lung cancer care from a reactive to a proactive discipline. The continuous refinement of computational algorithms, coupled with expanding genomic databases and improvements in imaging technology, positions radiogenomics at the forefront of precision oncology innovation.

Education and training of healthcare professionals will be critical to harness the full potential of this emerging field. As radiogenomics becomes integrated into clinical practice, multidisciplinary collaboration between radiologists, oncologists, pathologists, bioinformaticians, and genetic counselors will be essential to interpret complex data sets effectively and translate insights into actionable treatment plans.

In conclusion, radiogenomics embodies an exciting evolution in cancer medicine, blending centuries-old imaging techniques with cutting-edge genetic science. Shariaty and Pavlov’s study eloquently captures this transformative potential, illuminating how non-invasive imaging combined with genomic integration stands to redefine lung cancer diagnosis, prognosis, and therapy. The ripple effect of these advances promises not only to improve survival rates but also to enhance the quality of life for patients navigating this challenging disease.

As the field progresses, the dream of truly personalized, dynamic cancer care, enabled by the fusion of imaging and genomics, moves closer to clinical reality. Patients and clinicians may soon look back on earlier, more invasive methodologies as relics of a less informed era, where the therapeutic journey was guided largely by guesswork rather than comprehensive molecular and radiological intelligence. Radiogenomics heralds a future where lung cancer treatment is smarter, safer, and more effective than ever before.

Subject of Research: Radiogenomics in lung cancer care, integrating non-invasive imaging with genomic data.

Article Title: Radiogenomics: transforming lung cancer care through non-invasive imaging and genomic integration.

Article References:
Shariaty, F., Pavlov, V. Radiogenomics: transforming lung cancer care through non-invasive imaging and genomic integration. Med Oncol 42, 552 (2025). https://doi.org/10.1007/s12032-025-03118-0

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03118-0